ClinicalTrials.gg
CompletedNCT01349790Updated Jun 7, 2017Results posted

Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia

A Phase 3 interventional study of NewGam in Primary Thrombocytopenia, sponsored by Octapharma. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-06-07.

Sponsored by Octapharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic — 3 open to participants now, 3 under way, 1 of them phase 3. Immunoglobulins, Intravenous · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
7th of 13
40 · median 40
Started
2011
the only one that year
Phase 3
9 of 13
1 open now
Registered
8th of 13
by date
Lead sponsor
2 of 13
Octapharma

Among the 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic, this one is the 7th largest by enrollment, is the only one that started in 2011, is one of 9 in phase 3, and was the 8th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

3 of the 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Immunoglobulins, Intravenous

Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

NewGam is a newly developed human normal immunoglobulin solution for intravenous administration (IGIV). This study will evaluate the safety and efficacy of NewGam 10% in patients with primary immune thrombocytopenia.

Read the detailed description

The primary objective of the study is to assess the efficacy of NewGam in correcting the platelet count. The secondary objective of the study is to evaluate the safety of NewGam. Safety will be assessed by monitoring vital signs, physical examination, evaluation of adverse events (AE) and laboratory parameters, and viral safety testing.

03

Conditions studied

  • Primary Thrombocytopenia

Keywords

  • ITP
  • Primary immune thrombocytopenia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age of ≥ 18 and ≤ 65 years.
  2. Confirmed diagnosis of chronic primary immune thrombocytopenia (ITP) (diagnosed with a threshold count \< 100x10\^9/L) of at least 12 months duration.
  3. Platelet count of no more than 20x10\^9/L with or without bleeding manifestations.
  4. Freely given written from patient.
  5. Women of must have a negative result on a pregnancy test (human chorionic gonadotropin [HCG]-based assay) and need to practice using a method of proven reliability for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. Thrombocytopenia secondary to other diseases (such as acquired immunodeficiency syndrome [AIDS] or systemic lupus erythematosus [SLE]), or drug-related thrombocytopenia.
  2. Administration of intravenous immunoglobulin (IGIV), anti-D immunoglobulin or thrombopoietin receptor agonists, or other enhancing drugs (including or other immunomodulatory drugs) within 3 weeks before enrollment, except for:

    • Long-term therapy when the dose has been stable during the preceding 3 weeks and no dosage change is planned until study Day 22.
    • Long-term azathioprine, cyclophosphamide, or attenuated androgen therapy when the dose has been stable during the preceding 3 months and no dosage change is planned until study Day 22.
  3. Unresponsive to previous treatment with IGIV or anti-D immunoglobulin.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    NewGam

    Each participant received 1 g/kg NewGam intravenously on 2 consecutive days.

    Drug: NewGam

Interventions

  • DrugNewGam

    NewGam is a solution of human normal immunoglobulin 10% treated with solvent/detergent and nanofiltered for intravenous administration.

06

What researchers measure

Primary outcomes

  1. Percentage of Responders

    A responder is a study participant with an increase in platelets to ≥ 50x10\^9/L within 7 days after the first infusion, ie, by study Day 8.

    Time frame: Day 1 to Day 8

Secondary outcomes

  1. Percentage of Alternative Responders

    An alternative responder is a study participant with an increase in platelets to ≥ 30x10\^9/L and to at least double the baseline platelet count, confirmed on at least 2 occasions at least 7 days apart, and absence of bleeding.

    Time frame: Day 1 to Day 22

  2. Percentage of Complete Responders

    A complete responder is a study participant with an increase in platelets to ≥ 100x10\^9/L, confirmed on at least 2 occasions at least 7 days apart, and absence of bleeding.

    Time frame: Day 1 to Day 22

  3. Percentage of Alternative Responders Who Lost the Response

    An alternative responder who lost the response is a study participant who met the criterion for an alternative response but who then deteriorated, ie, their platelet count decreased to \< 30x10\^9/L, their platelet count decreased to less than double the baseline count, or bleeding occurred.

    Time frame: Day 1 to Day 22

  4. Percentage of Complete Responders Who Lost the Response

    A complete responder who lost the response is a study participant who met the criterion for a complete response but who then deteriorated, ie, their platelet count decreased to \< 100x10\^9/L or bleeding occurred.

    Time frame: Day 1 to Day 22

  5. Time to a Response

    A study participant had a response if their platelets increased to ≥ 50x10\^9/L within 7 days after the first infusion, ie, by study Day 8.

    Time frame: Day 1 to Day 8

  6. Time to an Alternative Response

    A study participant had a response if their platelets increased to ≥ 30x10\^9/L and to at least double the baseline platelet count, confirmed on at least 2 occasions at least 7 days apart, and absence of bleeding.

    Time frame: Day 1 to Day 22

  7. Time to a Complete Response

    A study participant had a complete response if their platelets increased to ≥ 100x10\^9/L, confirmed on at least 2 occasions at least 7 days apart, and absence of bleeding.

    Time frame: Day 1 to Day 22

  8. Duration of a Response

    The duration of a response was defined as the time from when a response was achieved until the platelet count fell below 50x10\^9/L.

    Time frame: Day 1 to Day 22

  9. Duration of an Alternative Response

    The duration of an alternative response was defined as the time from when an alternative response was achieved until the platelet count fell below 50x10\^9/L.

    Time frame: Day 1 to Day 22

  10. Duration of a Complete Response

    The duration of a complete response was defined as the time from when a complete response was achieved until the platelet count fell below 50x10\^9/L.

    Time frame: Day 1 to Day 22

  11. Platelet Count by Visit

    The platelet count at each study visit are presented.

    Time frame: Day 1 to Day 22

  12. Maximum Platelet Count

    The maximum platelet count achieved during the study is presented.

    Time frame: Day 1 to Day 22

  13. Percentage of Responders Who Achieved a Normal Platelet Count

    The percentage of responders who achieved a normal platelet count is presented.

    Time frame: Day 1 to Day 22

  14. Bleeding Intensity

    The percentage of participants with various intensities of overall bleeding, epistaxis (bleeding of the nose), oral bleeding, and skin bleeding graded as none, minor, mild, moderate, or severe at Baseline and Day 22 are reported.

    Time frame: Day 1 to Day 22

  15. Percentage of Participants Who Achieved a Platelet Count > 30x10^9/L

    The percentage of participants who achieved a platelet count \> 30x10\^9/L within 1 and 2 days after infusion is reported.

    Time frame: Day 1 to Day 2

07

Results

Posted Jun 7, 2017

Participant flow

Participant flow — Overall Study
MilestoneNewGam
Started40
Completed31
Not completed9
Withdrew: Investigator judgement3
Withdrew: Death2
Withdrew: Withdrawal by patient2
Withdrew: Adverse event1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryPercentage of Responders

A responder is a study participant with an increase in platelets to ≥ 50x10\^9/L within 7 days after the first infusion, ie, by study Day 8.

Time frame:
Day 1 to Day 8
Reported as:
Number · Percentage of participants
Percentage of Responders
Percentage of participantsNewGam
Percentage of Responders80.6 (63.98 to 91.81)
SecondaryPercentage of Alternative Responders

An alternative responder is a study participant with an increase in platelets to ≥ 30x10\^9/L and to at least double the baseline platelet count, confirmed on at least 2 occasions at least 7 days apart, and absence of bleeding.

Time frame:
Day 1 to Day 22
Reported as:
Number · Percentage of participants
Percentage of Alternative Responders
Percentage of participantsNewGam
Percentage of Alternative Responders66.7 (49.03 to 81.44)
SecondaryPercentage of Complete Responders

A complete responder is a study participant with an increase in platelets to ≥ 100x10\^9/L, confirmed on at least 2 occasions at least 7 days apart, and absence of bleeding.

Time frame:
Day 1 to Day 22
Reported as:
Number · Percentage of participants
Percentage of Complete Responders
Percentage of participantsNewGam
Percentage of Complete Responders50.0 (32.92 to 67.08)
SecondaryPercentage of Alternative Responders Who Lost the Response

An alternative responder who lost the response is a study participant who met the criterion for an alternative response but who then deteriorated, ie, their platelet count decreased to \< 30x10\^9/L, their platelet count decreased to less than double the baseline count, or bleeding occurred.

Time frame:
Day 1 to Day 22
Reported as:
Number · Percentage of participants
Percentage of Alternative Responders Who Lost the Response
Percentage of participantsNewGam
Percentage of Alternative Responders Who Lost the Response45.8 (25.55 to 67.18)
SecondaryPercentage of Complete Responders Who Lost the Response

A complete responder who lost the response is a study participant who met the criterion for a complete response but who then deteriorated, ie, their platelet count decreased to \< 100x10\^9/L or bleeding occurred.

Time frame:
Day 1 to Day 22
Reported as:
Number · Percentage of participants
Percentage of Complete Responders Who Lost the Response
Percentage of participantsNewGam
Percentage of Complete Responders Who Lost the Response77.8 (52.36 to 93.49)
SecondaryTime to a Response

A study participant had a response if their platelets increased to ≥ 50x10\^9/L within 7 days after the first infusion, ie, by study Day 8.

Time frame:
Day 1 to Day 8
Reported as:
Median · Days
Time to a Response
DaysNewGam
Time to a Response2.0 (1.00 to 2.00)
SecondaryTime to an Alternative Response

A study participant had a response if their platelets increased to ≥ 30x10\^9/L and to at least double the baseline platelet count, confirmed on at least 2 occasions at least 7 days apart, and absence of bleeding.

Time frame:
Day 1 to Day 22
Reported as:
Median · Days
Time to an Alternative Response
DaysNewGam
Time to an Alternative Response1.0 (1.00 to 2.00)
SecondaryTime to a Complete Response

A study participant had a complete response if their platelets increased to ≥ 100x10\^9/L, confirmed on at least 2 occasions at least 7 days apart, and absence of bleeding.

Time frame:
Day 1 to Day 22
Reported as:
Median · Days
Time to a Complete Response
DaysNewGam
Time to a Complete Response2.0 (2.00 to 2.00)
SecondaryDuration of a Response

The duration of a response was defined as the time from when a response was achieved until the platelet count fell below 50x10\^9/L.

Time frame:
Day 1 to Day 22
Reported as:
Median · Days
Duration of a Response
DaysNewGam
Duration of a Response14.0 (10.00 to 17.00)
SecondaryDuration of an Alternative Response

The duration of an alternative response was defined as the time from when an alternative response was achieved until the platelet count fell below 50x10\^9/L.

Time frame:
Day 1 to Day 22
Reported as:
Median · Days
Duration of an Alternative Response
DaysNewGam
Duration of an Alternative Response18.5 (17.00 to 20.00)
SecondaryDuration of a Complete Response

The duration of a complete response was defined as the time from when a complete response was achieved until the platelet count fell below 50x10\^9/L.

Time frame:
Day 1 to Day 22
Reported as:
Median · Days
Duration of a Complete Response
DaysNewGam
Duration of a Complete Response12.5 (10.00 to 16.00)
SecondaryPlatelet Count by Visit

The platelet count at each study visit are presented.

Time frame:
Day 1 to Day 22
Reported as:
Mean · 10^9 platelets/L
Platelet Count by Visit
10^9 platelets/LNewGam
Baseline8.8 ± 5.76
Day 241.6 ± 31.41
Day 3115.0 ± 85.58
Day 4154.6 ± 118.04
Day 5168.2 ± 149.89
Day 6179.3 ± 178.64
Day 7206.3 ± 195.75
Day 8186.5 ± 205.44
Day 1588.1 ± 130.07
Day 22/End of treatment41.4 ± 65.48
SecondaryMaximum Platelet Count

The maximum platelet count achieved during the study is presented.

Time frame:
Day 1 to Day 22
Reported as:
Mean · 10^9 platelets/L
Maximum Platelet Count
10^9 platelets/LNewGam
Maximum Platelet Count236.9 ± 205.18
SecondaryPercentage of Responders Who Achieved a Normal Platelet Count

The percentage of responders who achieved a normal platelet count is presented.

Time frame:
Day 1 to Day 22
Reported as:
Number · Percentage of participants
Percentage of Responders Who Achieved a Normal Platelet Count
Percentage of participantsNewGam
Percentage of Responders Who Achieved a Normal Platelet Count79.3 (60.28 to 92.01)
SecondaryBleeding Intensity

The percentage of participants with various intensities of overall bleeding, epistaxis (bleeding of the nose), oral bleeding, and skin bleeding graded as none, minor, mild, moderate, or severe at Baseline and Day 22 are reported.

Time frame:
Day 1 to Day 22
Reported as:
Number · Percentage of participants
Bleeding Intensity
Percentage of participantsNewGam
Overall - Total - Baseline100.0
Overall - Total - Day 8100.0
Overall - Total - Day 22100.0
Overall - None - Baseline36.1
Overall - None - Day 891.2
Overall - None - Day 2272.2
Overall - Minor - Baseline38.9
Overall - Minor - Day 85.9
Overall - Minor - Day 2219.4
Overall - Mild - Baseline5.6
Overall - Mild - Day 82.9
Overall - Mild - Day 222.8
Overall - Moderate - Baseline19.4
Overall - Moderate - Day 80.0
Overall - Moderate - Day 222.8
Overall - Severe - Baseline0.0
Overall - Severe - Day 80
Overall - Severe - Day 222.8
Epistaxis - Total - Baseline100.0
Epistaxis - Total - Day 22100.0
Epistaxis - None - Baseline83.3
Epistaxis - None - Day 2291.7
Epistaxis - Minor - Baseline8.3
Epistaxis - Minor - Day 228.3
Epistaxis - Mild - Baseline5.6
Epistaxis - Mild - Day 220.0
Epistaxis - Moderate - Baseline2.8
Epistaxis - Moderate - Day 220.0
Epistaxis - Severe - Baseline0.0
Epistaxis - Severe - Day 220.0
Oral bleeding - Total - Baseline100.0
Oral bleeding - Total - Day 22100.0
Oral bleeding - None - Baseline75.0
Oral bleeding - None - Day 2286.1
Oral bleeding - Minor - Baseline13.9
Oral bleeding - Minor - Day 228.3
Oral bleeding - Mild - Baseline0.0
Oral bleeding - Mild - Day 222.8
Oral bleeding - Moderate - Baseline5.6
Oral bleeding - Moderate - Day 222.8
Oral bleeding - Severe - Baseline5.6
Oral bleeding - Severe - Day 220.0
Skin bleeding - Total - Baseline100.0
Skin bleeding - Total - Day 22100.0
Skin bleeding - None - Baseline41.7
Skin bleeding - None - Day 2277.8
Skin bleeding - Minor - Baseline25.0
Skin bleeding - Minor - Day 2222.2
Skin bleeding - Mild - Baseline27.8
Skin bleeding - Mild - Day 220.0
Skin bleeding - Moderate - Baseline5.6
Skin bleeding - Moderate - Day 220.0
Skin bleeding - Severe - Baseline0.0
Skin bleeding - Severe - Day 220.0
SecondaryPercentage of Participants Who Achieved a Platelet Count > 30x10^9/L

The percentage of participants who achieved a platelet count \> 30x10\^9/L within 1 and 2 days after infusion is reported.

Time frame:
Day 1 to Day 2
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a Platelet Count > 30x10^9/L
Percentage of participantsNewGam
Day 155.0
Day 277.5

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NewGam—6/40 (15%)30/40 (75%)
Most frequent serious events
Most frequent serious events
EventNewGam
Autoimmune thrombocytopeniaBlood and lymphatic system disorders3/40
PneumonitisRespiratory, thoracic and mediastinal disorders1/40
DysphagiaGastrointestinal disorders1/40
Cerebral haematomaNervous system disorders1/40
Meningitis asepticNervous system disorders1/40
PneumoniaInfections and infestations1/40
Respiratory failureRespiratory, thoracic and mediastinal disorders1/40
SepsisInfections and infestations1/40
Most frequent other events
Most frequent other events
EventNewGam
HeadacheNervous system disorders17/40
PyrexiaGeneral disorders9/40
Autoimmune thrombocytopeniaBlood and lymphatic system disorders6/40
NauseaGastrointestinal disorders6/40
AnaemiaBlood and lymphatic system disorders5/40
VomitingGastrointestinal disorders4/40
DizzinessNervous system disorders3/40
Idiopathic thrombocytopenic purpuraBlood and lymphatic system disorders2/40
AstheniaGeneral disorders2/40
ChillsGeneral disorders2/40

Baseline characteristics

Safety set: All participants enrolled in the study who received at least part of 1 dose of NewGam.

Age, Continuous
Age, Continuous(years)NewGam
Mean36.7 ± 15.34
Sex: Female, Male
Sex: Female, Male(Participants)NewGam
Female17
Male23
08

Study locations

1 site
  • Abdulgabar Salama
    Berlin, Germany
09

References and documents

Publications

  • Arbach O, Taumberger AB, Wietek S, Cervinek L, Salama A. Efficacy and safety of a new intravenous immunoglobulin (Panzyga(R) ) in chronic immune thrombocytopenia. Transfus Med. 2019 Feb;29(1):48-54. doi: 10.1111/tme.12573. Epub 2019 Jan 27. PubMed 30687970 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 3 years 11 months after primary completion. A results delay was requested in Jun 2015.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2011
First posted
May 9, 2011
Start
Oct 2011
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Results delay requested
Jun 5, 2015
Results first posted
Jun 7, 2017
Last update
Jun 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01349790
Lead sponsor
Octapharma
Responsible party
Sponsor
First posted
May 9, 2011
Start date
Oct 2011
Primary completion
Jul 2013
Completion
Jul 2013
Results posted
Jun 7, 2017
Last update
Jun 7, 2017

Study contacts

Abdulgabar Salama, MD
principal investigator · Universitätsklinikum Charite, Med. Fakultät der Humboldt-Universität Berlin
Wolfgang Frenzel, MD
study director · Octapharma AG

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion